Results 201 to 210 of about 119,842 (257)

Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV. [PDF]

Antimicrob Agents Chemother
Maranchick NF, Martyn-Dickens C, Enimil A, Yang H, Amissah AK, Dompreh A, Bosomtwe D, Sly-Moore E, Opoku T, Frimpong Appiah A, Asiedu P, Antwi S, Scheetz MH, Peloquin CA, Kwara A.   +14 more
europepmc   +1 more source

Population Pharmacokinetics and Clinical Application of Vancomycin in Critically Ill Adults: A NONMEM-Based Review. [PDF]

Drug Des Devel Ther
Husheng H, Wang Y, He Y, Shen F, Chen J.
europepmc   +1 more source

Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ooi QX, Brendel K, van Beek S, Zdovc JA, Bardol M, Dehez M.   +5 more
europepmc   +1 more source

Genetic and nongenetic factors affecting vancomycin population pharmacokinetics and pharmacodynamics: A systematic review.

Indian J Pharmacol
Pradana DA, Marfianti E, Wibowo A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Population Pharmacokinetics of Lamotrigine

Therapeutic Drug Monitoring, 2001
The present study estimated the population pharmacokinetics of lamotrigine in patients receiving oral lamotrigine therapy with drug concentration monitoring, and determined intersubject and intrasubject variability. A total of 129 patients were analyzed from two clinical sites. Of these, 124 patients provided sparse data (198 concentration-time points);
Chan, V., Morris, R., Ilet, K., Tett, S.
openaire   +5 more sources

Population pharmacokinetics of oxaliplatin

Cancer Chemotherapy and Pharmacology, 2002
The objective of this study was to explore correlations between a variety of covariates and oxaliplatin ultrafilterable and blood pharmacokinetic parameters. Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed. Plasma ultrafilterable, blood, and
Jean-Pierre, Delord, Amine, Umlil, Rosine, Guimbaud, Nicolas, Grégoire, Thierry, Lafont, Pierre, Canal, Roland, Bugat, Etienne, Chatelut   +7 more
openaire   +2 more sources

Pharmacokinetics in special populations

Drug Metabolism Reviews, 2009
Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs ...
Italo, Poggesi, Margherita Strolin, Benedetti, Rhys, Whomsley, Sophie, Le Lamer, Mathieu, Molimard, Jean-Baptiste, Watelet   +5 more
openaire   +2 more sources

Population pharmacokinetics of ramosetron

Journal of Pharmacokinetics and Pharmacodynamics, 2015
Ramosetron is a selective serotonergic 5-hydroxy-tryptamine receptor 3 antagonist that is used to prevent and treat postoperative nausea and vomiting. This study aimed to characterize the population pharmacokinetics of ramosetron in patients undergoing surgery with general anesthesia.
Seong Heon Lee, Soo Young Cho, Kyung Yeon Yoo, Seongwook Jeong   +3 more
openaire   +2 more sources

Population Pharmacokinetics

Clinical Pharmacokinetics, 1999
The application of population approaches to drug development is recommended in several US Food and Drug Administration (FDA) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge upon drug safety and efficacy.
H, Sun, E O, Fadiran, C D, Jones, L, Lesko, S M, Huang, K, Higgins, C, Hu, S, Machado, S, Maldonado, R, Williams, M, Hossain, E I, Ette   +11 more
openaire   +2 more sources